Influence of process parameters in the ASES process on particle properties of budesonide for pulmonary delivery

被引：37

作者：

Steckel, H ^{[1
]}

Pichert, L ^{[1
]}

Müller, BW ^{[1
]}

机构：

[1] Univ Kiel, Dept Pharmaceut & Biopharmaceut, D-24118 Kiel, Germany

来源：

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS | 2004年 / 57卷 / 03期

关键词：

budesonide; supercritical fluid; aerosol solvent extraction system; dry powder inhalation; aerodynamic diameter; micronization;

D O I：

10.1016/j.ejpb.2004.01.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Budesonide was micronized by precipitation in supercritical carbon dioxide by using the aerosol solvent extraction system at various process conditions. The process is characterised by spraying an organic solution of budesonide into the supercritical fluid (SCF), precipitation of the drug in the SCF and extraction and recovery of the solvent. The micronized budesonide particles were characterized physicochemically for their morphology, crystallinity, size distribution and for their aerodynamic behaviour. The particle size distribution of the powder products was similar, regardless of the process conditions used for the crystallization. Also, the morphology of the particles did not differ between the batches. However, the aerodynamic properties of the precipitated batches were significantly different between the batches produced and as compared to a jet-milled budesonide powder. In conclusion, the process conditions in the SCF precipitation may influence the aerodynamic properties, although other physico-chemical parameters appear to be similar. (C) 2004 Elsevier B.V. All rights reserved.

引用

页码：507 / 512

页数：6

共 16 条

[1] Control of the physical form of salmeterol xinofoate [J].

Beach, S ;

Latham, D ;

Sidgwick, C ;

Hanna, M ;

York, P .

ORGANIC PROCESS RESEARCH & DEVELOPMENT, 1999, 3 (05) :370-376

[2] PRODUCTION OF SPRAY-DRIED SALBUTAMOL SULFATE FOR USE IN DRY POWDER AEROSOL FORMULATION [J].

CHAWLA, A ;

TAYLOR, KMG ;

NEWTON, JM ;

JOHNSON, MCR .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 108 (03) :233-240

[3]

GANDERTON D, 1999, J AEROSOL MED, V12, P3, DOI DOI 10.1089/JAM.1999.12.SUPPL_1.S-3

[4] Increase in the specific surface area of budesonide during storage postmicronization [J].

Joshi, V ;

Dwivedi, S ;

Ward, GH .

PHARMACEUTICAL RESEARCH, 2002, 19 (01) :7-12

[5] Micronization of drugs using supercritical carbon dioxide [J].

Kerc, J ;

Srcic, S ;

Knez, Z ;

Sencar-Bozic, P .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 182 (01) :33-39

[6]

MULLER BW, 1989, Patent No. 3744329

[7]

PARROT EL, 1990, ENCY PHARM TECHNOLOG, V3, P1019

[8] Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process [J].

Rasenack, N ;

Steckel, H ;

Müller, BW .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (01) :35-44

[9] A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid [J].

Rogers, TL ;

Nelsen, AC ;

Hu, JH ;

Brown, JN ;

Sarkari, M ;

Young, TJ ;

Johnston, KP ;

Williams, RO .

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2002, 54 (03) :271-280

[10] Solution-based particle formation of pharmaceutical powders by supercritical or compressed fluid CO2 and cryogenic spray-freezing technologies [J].

Rogers, TL ;

Johnston, KP ;

Williams, RO .

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2001, 27 (10) :1003-1015

← 1 2 →